Hi-Risk/Recurrent/Advanced PrCa Video Chat, Oct. 13, 2026

by | Oct 14, 2026 | High Risk/Recurrent/Advanced, High Risk/Recurrent/Advanced Prostate Cancer, mCRPC, mHSPC, Prostate Cancer, Recorded Groups, Uncategorized

Intermediate Risk Prostate Cancer Graphic

Hi-Risk/Recurrent/Advanced PrCa Video Chat, Oct. 13, 2026

AnCan IS ON SUBSTACK… find us at https://ancanspeak.substack.com/. Please sign up. We’re posting the best of all our Reminders.

AnCan thanks the following sponsors for making this recording possible: Novartis, Telix and Blue Earth Diagnostics.
Views expressed in this Recording are solely the opinion of AnCan Foundation, our Moderators and Participants.

AnCan does not accept sponsored promotion. Any drugs, protocols or devices discussed are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.

AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download

All AnCan’s groups are free and drop-in … join us in person sometime! You can find out more about our 12 monthly prostate cancer meetings at https://ancan.org/prostate-cancer/ Sign up to receive a weekly Reminder/Newsletter for this Group or others at https://ancan.org/contact-us/

Join our other free and drop in groups:
Men (Only) Speaking Freely…1st & 3rd Thursdays @ 8.00 pm Eastern https://ancan.org/men-speaking-freely/
Veterans Healthcare Navigation… 1st & 3rd Tuesdays @ 8.00 pm Eastern Schmier Room https://ancan.org/veterans/
Veterans Speaking freely… 4th Tuesday @ @ 8.00 pm Eastern Schmier Room

Editor’s Pick:  

Topics Discussed

Younger Newbie graduates to our Group post RRP; treated after 20 yrs of AS.. but in the wrong group; finding the best trial for Frank; Bx cannot confirm PrCa; spot RT may be the ticket; all sable during IHT; RT to commence this month; what’s in Dr. Guancial’s name?; PSMA scans pos doublet are negative; when and how often to PSM scan; GU MO denies Pluvicto post triplet though scans light up; Gent decides to start TRT; brief discussion of HLD-0915

Chat

  • Bob Schwartz, USN, Venice, FL. sent: 3:17 PM

    I can agree as to the hospital sling I received last time, for my other shoulder surgery. Which was why I was glad to hear your recommendation of a better one, prior to my upcoming surgery. Wish I didn’t need the surgery, but old age & past injuries, are catching up with me.

  • Jim Ekrut, Fort Worth TX sent: 3:50 PM

    md anderson for regen: https://www.mdanderson.org/patients-family/diagnosis-treatment/clinical-trials/clinical-trials-index/clinical-trials-detail.ID2022-0448.html

  • TonyFig sent: 4:19 PM

    Will the Founders picture be on the mug?

  • rick davis sent: 4:20 PM

    Nope Tony Fig

    Steve L…. Hold tight and we’ll have the mugs available in our shop before long. You can order and take care of biz.

  • Alfredo in Wimberley, TX sent: 4:31 PM

    Family calling – I must drop off now. Best wishes to all!

  • Steve Schuler (Seattle) sent: 4:31 PM

    I wondered why I hadn’t heard anything… Answer: beurocrac

    (can’t spell it though… :^(

  • Len Sierra sent: 4:36 PM

    JAMA Oncol. 2019, 5, 856-863. In the first prospective trial of 68Ga-PSMA-11 PET/CT for BRPC, which included 635 patients, detection rates were 38% for PSA levels of < 1.0 ng/mL (n = 79), 84% for 1.0 to 2.0 (n=89), 86% for 2.0 to 5.0 (n=158), and 94% for >5.0. (BRPC = Bio-Recurrent PC)

  • Steve Schuler (Seattle) sent: 4:41 PM

    a meta-observation is that most therapies that are initially only for end stage move earlier in treatment where their use there improves things.  improves at least in the CSS sense, not necessarily in the OS sense

  • Len Sierrasent: 4:46 PM

    New Terminology: • Androgen Pathway Modulator Sensitive: Tumors that continue to respond to or are controlled by androgen pathway suppression/blockade. • Androgen Pathway Modulator Resistant: Tumors that progress despite treatment targeting the androgen pathway

  • Steve – Seattle sent: 4:49 PM

    My Calendar has the Ancan Seattle dinner scheduled for Sunday but I don’t have any details.

  • rick davis sent: 4:51 PM

    Stand by as I said.

  • Steve Schuler (Seattle) sent: 4:53 PM

    I’ve got to drop, but I will “stand by” to hear about Sunday. I will be at the conference Saturday, probably at Fred Hutch which I assume must be a video screen but in the FH building… That way I get a free sandwich I think :^)

  • RJ Smith (Seattle) sent: 4:54 PM

    Same here–see you there Steve!

  • rick davis sent: 4:54 PM

    : NCT06800313  HLD0915

  • George Kander

    sent: 4:56 PM

    Family calls – have to go. Thanks everyone and hopefully see you at dinner Friday in Portland – Chhers

  • Julian – Houston sent: 4:57 PM

    Another great discussion!!!